Literature DB >> 10323584

Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats.

J C Bentley1, A Bourson, F G Boess, K C Fone, C A Marsden, N Petit, A J Sleight.   

Abstract

1. The present study examined the effects of the selective 5-HT6 receptor antagonist 4-amino-N-(2, 6 bis-methylamino-pyrimidin-4-yl)-benzene sulphonamide (Ro 04-6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats (230-300 g). 2. In non-quantified behavioural observations, animals treated with Ro 04-6790 (3, 10 or 30 mg kg(-1), i.p) showed no overt behavioural signs except a dose-dependent reduction in locomotor activity and a behavioural syndrome of stretching, yawning and chewing. The latter behaviour was most pronounced between 30 and 90 min following the administration of Ro 04-6790. 3. Detailed analysis of the stretching and yawning behaviour showed that Ro 04-6790 (3, 10 or 30 mg kg(-1), i.p.) dose-dependently induced stretching. The number of stretches observed following treatment with either Ro 04-6790 (10 mg kg(-1) i.p.) or Ro-04-6790 (30 mg kg(-1), i.p.) was significantly greater than that observed in saline-treated rats. The yawning behaviour, however, was not dose-dependent nor was the number of yawns in any of the drug treated groups significantly greater than in those treated with saline. 4. Pretreatment (30 min) with the non-selective muscarinic antagonists scopolamine (0.1, 0.3 or 1 mg kg(-1), i.p.) and atropine (0.3, 1 or 3 mg kg(-1), s.c.) but not methylatropine (1, 3 or 10 mg kg(-1), s.c) significantly inhibited stretching induced by Ro 04-6790 (30 mg kg(-1), i.p.). 5. The dopamine D2-like receptor antagonist, haloperidol (0.03, 0.1 or 0.3 mg kg(-1), s.c.) given at the same time as Ro 04-6790 (30 mg kg(-1), i.p.) had no effect on the stretching induced by the 5-HT6 antagonist. 6. These data suggest that systemic injection of the 5-HT6 antagonist, Ro 04-6790, produces a stretching behaviour that appears to be mediated by an increase in cholinergic neurotransmission in the CNS and which could be a useful functional correlate for 5-HT6 receptor blockade. There is no evidence for dopamine D2-like receptor involvement in this behaviour.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323584      PMCID: PMC1565929          DOI: 10.1038/sj.bjp.0702445

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry.

Authors:  R P Ward; M W Hamblin; J E Lachowicz; B J Hoffman; D R Sibley; D M Dorsa
Journal:  Neuroscience       Date:  1995-02       Impact factor: 3.590

Review 2.  The cholinergic hypothesis of geriatric memory dysfunction.

Authors:  R T Bartus; R L Dean; B Beer; A S Lippa
Journal:  Science       Date:  1982-07-30       Impact factor: 47.728

3.  Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.

Authors:  F J Monsma; Y Shen; R P Ward; M W Hamblin; D R Sibley
Journal:  Mol Pharmacol       Date:  1993-03       Impact factor: 4.436

4.  Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions.

Authors:  C Wahlestedt; E Golanov; S Yamamoto; F Yee; H Ericson; H Yoo; C E Inturrisi; D J Reis
Journal:  Nature       Date:  1993-05-20       Impact factor: 49.962

5.  Behavioural evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist.

Authors:  F Ferrari; F Pelloni; D Giuliani
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.

Authors:  C Wahlestedt; E M Pich; G F Koob; F Yee; M Heilig
Journal:  Science       Date:  1993-01-22       Impact factor: 47.728

7.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.

Authors:  M Ruat; E Traiffort; J M Arrang; J Tardivel-Lacombe; J Diaz; R Leurs; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

8.  In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.

Authors:  L W Zhou; S P Zhang; Z H Qin; B Weiss
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

9.  Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.

Authors:  B L Roth; S C Craigo; M S Choudhary; A Uluer; F J Monsma; Y Shen; H Y Meltzer; D R Sibley
Journal:  J Pharmacol Exp Ther       Date:  1994-03       Impact factor: 4.030

Review 10.  Behavioral effects of ACTH and MSH peptides.

Authors:  A Bertolini; G L Gessa
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

View more
  16 in total

1.  Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist.

Authors:  C Routledge; S M Bromidge; S F Moss; G W Price; W Hirst; H Newman; G Riley; T Gager; T Stean; N Upton; S E Clarke; A M Brown; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Biodistribution and radiation dosimetry of the serotonin 5-HT₆ ligand [¹¹C]GSK215083 determined from human whole-body PET.

Authors:  Robert A Comley; Cristian Salinas; Romina Mizrahi; Irina Vitcu; Alvina Ng; William Hallett; Nicholas Keat; Alan A Wilson; Eugenii A Rabiner; Marc Laruelle; Sylvain Houle
Journal:  Mol Imaging Biol       Date:  2012-08       Impact factor: 3.488

3.  5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.

Authors:  Paula D Hatcher; Verity J Brown; David S Tait; Simon Bate; Philip Overend; Jim J Hagan; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

4.  In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate.

Authors:  L A Dawson; H Q Nguyen; P Li
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Neuropharmacological profile of aqueous extract of Anaphe venata larva (Notondotidae) in rats.

Authors:  K D S Bamitale; M A Akanmu; Otas E Ukponmwan
Journal:  Afr J Tradit Complement Altern Med       Date:  2011-04-02

6.  Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

Authors:  W D Hirst; J A Minton; S M Bromidge; S F Moss; A J Latter; G Riley; C Routledge; D N Middlemiss; G W Price
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.

Authors:  B Marcos; T T Chuang; F J Gil-Bea; M J Ramirez
Journal:  Br J Pharmacol       Date:  2008-07-14       Impact factor: 8.739

Review 8.  5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.

Authors:  Neil Upton; Tsu Tshen Chuang; Ann J Hunter; David J Virley
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 9.  Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders.

Authors:  Bryan L Roth; S Mohammad Hanizavareh; Andrew E Blum
Journal:  Psychopharmacology (Berl)       Date:  2003-12-02       Impact factor: 4.530

10.  Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790.

Authors:  Marie L Woolley; Charles A Marsden; Andrew J Sleight; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.